Piper Sandler downgraded Tourmaline Bio (TRML) to Neutral from Overweight with a price target of $48, down from $65, after the company agreed to be acquired by Novartis (NVS) for $1.4B in cash, or $48 per share.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRML:
- Tourmaline Bio downgraded to Neutral from Buy at H.C. Wainwright
- Tourmaline Bio downgraded to Hold from Buy at Truist
- Tourmaline Bio downgraded to Neutral from Buy at Chardan
- Tourmaline Bio downgraded to Hold from Buy at Jefferies
- Nebius enters AI pact with Microsoft, Teck to combine with Anglo: Morning Buzz